Arizona lawsuit blames Zicam spray for loss of smell

Key points
- Users of the nasal spray Zicam Cold Remedy have filed a proposed class action lawsuit, claiming the popular over-the-counter product robbed them of their sense of smell.
- A spokesman for Phoenix-based Matrixx Initiatives Inc., which distributes Zicam, on Monday said the lawsuit had been prompted by media reports on a flawed medical study and was without merit.
- The lawsuit also seeks unspecified damages from retailers such as Walgreen Co., Wal-Mart Stores Inc., Costco Wholesale Corp., Kroger Co., Rite Aid Corp., Safeway Inc.
- Officials at Walgreen, Kroger and Rite Aid had no immediate comment on the lawsuit.
Users of the nasal spray Zicam Cold Remedy have filed a proposed class action lawsuit, claiming the popular over-the-counter product robbed them of their sense of smell.
A spokesman for Phoenix-based Matrixx Initiatives Inc., which distributes Zicam, on Monday said the lawsuit had been prompted by media reports on a flawed medical study and was without merit.
The lawsuit also seeks unspecified damages from retailers such as Walgreen Co., Wal-Mart Stores Inc., Costco Wholesale Corp., Kroger Co., Rite Aid Corp., Safeway Inc.
Officials at Walgreen, Kroger and Rite Aid had no immediate comment on the lawsuit. Officials at Wal-Mart, Costco and Safeway could not be reached for comment.
The lawsuit, filed in Arizona Superior Court last month and made public on Monday, claims Matrixx and Botanical Laboratories Inc. sold the homeopathic spray and gel without proper testing.
Zinc nasal sprays have been touted by doctors and some researchers as a way to cut the length and severity of colds. But a University of Colorado study, presented in the American Journal of Rhinology's May-June issue, linked zinc sprays to loss of the sense of smell, or anosmia.
The company has strongly defended Zicam as safe, and contends the University of Colorado research relied on a "very, very weak anecdotal report about one man in his 50s who had a lot of risk factors for loss of smell."
"The product was marketed since 1999 and this was not an issue until this (study) got into the media," said Robert Murphy, a spokesman for Matrixx.
Since the start of the year, shares of Matrixx have lost about 27 percent. The stock has rebounded from a low of $7.26 in mid-July and closed on Monday at $13.01 on Nasdaq, down 1.4 percent on the day.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Addiction →
NewsStudy links Prozac, Paxil use with birth defects
A sweeping government study of thousands of women has found links between the older antidepressants Prozac and Paxil and birth defects, but has cleared other popular treatments in the class, including Celexa, Lexapro…
13 July 2015
NewsMarijuana users substitute alcohol at 21
A recent study looked at marijuana and alcohol use in people between the ages of 18 and 24. It's probably not surprising that the results show a drastic increase in alcohol consumption in people just over 21; after all,…
8 July 2015
NewsTwo techniques of temporal migraine surgery are 'equally effective'
Two migraine surgery techniques targeting a specific "trigger site" are both highly effective in reducing the frequency and severity of migraine headaches, according to a randomized trial in the July issue of Plastic…
1 July 2015
